American Regent’s HEART-FID trial for INJECTAFER fails to meet primary endpoint
American Regent, Inc., a subsidiary of Daiichi Sankyo Group, has announced disappointing results from its phase 3 HEART-FID trial of INJECTAFER (ferric carboxymaltose injection) for the treatment of iron deficiency in adult heart failure patients with reduced ejection fraction (HFrEF). Despite a numerical improvement in certain outcomes, the study failed to achieve statistical significance for […]